XTX Markets’s Alaunos Therapeutics TCRT Stock Holding History

XTX Markets’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-74	Closed	-$28K	–	250
2020 Q3	$28K	Buy	+74	New	+$32.7K	0.13%	96

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

XTX Markets's TCRT Position: Q4 2020 in Review

XTX Markets sold out of Alaunos Therapeutics (TCRT) in Q4 2020, closing a stake of 74 shares — an estimated $28K sold.

XTX Markets first reported a position in TCRT in Q3 2020 and held it in 1 quarter. The position peaked at $28K in Q3 2020. 156 funds tracked by Wall St. Rank hold TCRT as of Q4 2020.

XTX Markets reported no remaining Alaunos Therapeutics position as of Q4 2020 after selling out during the quarter.
XTX Markets sold 74 Alaunos Therapeutics shares in Q4 2020, an estimated $28K.
XTX Markets first reported a position in Alaunos Therapeutics in Q3 2020 and held it in 1 quarter.
XTX Markets's Alaunos Therapeutics position peaked at $28K in Q3 2020.
156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.